Adjusting for Unknown Bias in Noninferiority Clinical Trials

被引:9
|
作者
Odem-Davis, Katherine [1 ]
Fleming, Thomas R. [2 ,3 ]
机构
[1] Univ Washington, Ctr Biomed Stat, Seattle, WA 98195 USA
[2] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
来源
STATISTICS IN BIOPHARMACEUTICAL RESEARCH | 2013年 / 5卷 / 03期
关键词
Active control; Constancy; Delta; Equivalence; Margin; NON-INFERIORITY TRIALS; DESIGN;
D O I
10.1080/19466315.2013.795910
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Evaluation of noninferiority is based on ruling out a threshold for what would constitute unacceptable loss of efficacy of an experimental treatment relative to an active comparator "Standard." This threshold, the "noninferiority margin," is often based on preservation of a percentage of Standard's effect. To obtain an estimate of this effect to be used in the development of the "noninferiority margin," data are needed from earlier trials comparing Standard to Placebo if the noninferiority trial does not have a Placebo arm. This approach often provides a biased overestimate of Standard's true effect in the setting of the current noninferiority study. We describe two commonly used noninferiority margin methods that adjust for this bias, the two-confidence interval (95-95), and the Synthesis margins. However, the added " variance inflation" adjustment made by 95-95 margin diminishes with increasing information from historical trial(s), and the Synthesis margin is based on a strong assumption that the relative bias is known. We introduce an alternative "Bias-adjusted" margin addressing vulnerabilities of each by attenuating the estimate and by accounting for uncertainty in the true level of bias. Examples and asymptotic estimates of noninferiority hypothesis rejection rates in the proportional hazards setting are used to compare methods.
引用
收藏
页码:248 / 258
页数:11
相关论文
共 50 条
  • [21] Missing Data in Noninferiority Trials
    Wiens, Brian L.
    Rosenkranz, Gerd K.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2013, 5 (04): : 383 - 393
  • [22] Protocol adherence rates in superiority and noninferiority randomized clinical trials published in high impact medical journals
    Bamat, Nicolas A.
    Ekhaguere, Osayame A.
    Zhang, Lingqiao
    Flannery, Dustin D.
    Handley, Sara C.
    Herrick, Heidi M.
    Ellenberg, Susan S.
    CLINICAL TRIALS, 2020, 17 (05) : 552 - 559
  • [23] THE REPORTING QUALITY OF NONINFERIORITY TRIALS USING INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS
    Jia, Huixun
    Li, Tong
    Wan, Hongli
    Wu, Zhenyu
    Sun, Xiaodong
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2023, 43 (02): : 243 - 253
  • [24] Comparative Effectiveness Clinical Trials in Psychiatry: Superiority, Noninferiority, and the Role of Active Comparators
    Leon, Andrew C.
    JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (10) : 1344 - 1349
  • [25] The choice of the noninferiority margin in clinical trials was driven by baseline risk, type of primary outcome, and benefits of new treatment
    Gayet-Ageron, Angele
    Agoritsas, Thomas
    Rudaz, Sandrine
    Courvoisier, Delphine
    Perneger, Thomas
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2015, 68 (10) : 1144 - 1151
  • [26] Randomization as a basis for inference in noninferiority trials
    Wiens, Brian L.
    PHARMACEUTICAL STATISTICS, 2006, 5 (04) : 265 - 271
  • [27] Design issues in noninferiority/equivalence trials
    Hwang, IK
    Morikawa, T
    DRUG INFORMATION JOURNAL, 1999, 33 (04): : 1205 - 1218
  • [28] The Need for Combined Assessment of Multiple Outcomes in Noninferiority Trials in Oncology
    Jatoi, Ismail
    Gail, Mitchell H.
    JAMA ONCOLOGY, 2020, 6 (03) : 420 - 424
  • [29] Interpretation and Inference in Noninferiority Randomized Controlled Trials in Drug Research
    Wangge, G.
    Klungel, O. H.
    Roes, K. C. B.
    de Boer, A.
    Hoes, A. W.
    Knol, M. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (03) : 420 - 423
  • [30] Inferiority Index and Margin in Noninferiority Trials
    Li, Gang
    Chi, George Y. H.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2011, 3 (02): : 288 - 301